Messing M - Search Results

1

Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.

Gordon AN, Hancock KC, Matthews CM, Messing M, Stringer CA, Doherty MG, Teneriello M. Gordon AN, et al. Among authors: messing m. Gynecol Oncol. 2002 Apr;85(1):129-35. doi: 10.1006/gyno.2001.6581. Gynecol Oncol. 2002. PMID: 11925132 Clinical Trial.

2

Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.

Gordon AN, Asmar L, Messing MJ, Street DG, Pippitt CH Jr, Bailey CL, Savage J, Young JA. Gordon AN, et al. Gynecol Oncol. 2004 Aug;94(2):533-9. doi: 10.1016/j.ygyno.2004.05.021. Gynecol Oncol. 2004. PMID: 15297200 Clinical Trial.

3

Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.

Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, Boehm KA, Williams A, Asmar L. Teneriello MG, et al. Among authors: messing mj. J Clin Oncol. 2009 Mar 20;27(9):1426-31. doi: 10.1200/JCO.2008.18.9548. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224848 Clinical Trial.

4

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.

Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, Ma B, Hodge JP, Lager JJ. Friedlander M, et al. Among authors: messing mj. Gynecol Oncol. 2010 Oct;119(1):32-7. doi: 10.1016/j.ygyno.2010.05.033. Epub 2010 Jun 27. Gynecol Oncol. 2010. PMID: 20584542 Clinical Trial.

5

Salvage surgery for chemorefractory ovarian germ cell tumors.

Munkarah A, Gershenson DM, Levenback C, Silva EG, Messing MJ, Morris M, Burke TW. Munkarah A, et al. Among authors: messing mj. Gynecol Oncol. 1994 Nov;55(2):217-23. doi: 10.1006/gyno.1994.1280. Gynecol Oncol. 1994. PMID: 7959287 Clinical Trial.

6

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.

Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, Messing M, Stepan DE, Dutcus CE, Wu J, Schmidt EV, Orlowski R, Sachdev P, Shumaker R, Casado Herraez A. Makker V, et al. Among authors: messing m. J Clin Oncol. 2020 Sep 10;38(26):2981-2992. doi: 10.1200/JCO.19.02627. Epub 2020 Mar 13. J Clin Oncol. 2020. PMID: 32167863 Free PMC article. Clinical Trial.

7

Retroperitoneal dissemination of cervix cancer following surgical staging.

Messing MJ, Flickinger FW, Gallup DG. Messing MJ, et al. Gynecol Oncol. 1994 May;53(2):269-73. doi: 10.1006/gyno.1994.1129. Gynecol Oncol. 1994. PMID: 8188093

8

Primary treatment failure in patients with malignant ovarian germ cell neoplasms.

Messing MJ, Gershenson DM, Morris M, Burke TW, Kavanagh JJ, Wharton JT. Messing MJ, et al. Int J Gynecol Cancer. 1992 Nov;2(6):295-300. doi: 10.1046/j.1525-1438.1992.02060295.x. Int J Gynecol Cancer. 1992. PMID: 11576272

9

Mitotic count, nuclear atypia, and immunohistochemical determination of Ki-67, c-myc, p21-ras, c-erbB2, and p53 expression in granulosa cell tumors of the ovary: mitotic count and Ki-67 are indicators of poor prognosis.

King LA, Okagaki T, Gallup DG, Twiggs LB, Messing MJ, Carson LF. King LA, et al. Among authors: messing mj. Gynecol Oncol. 1996 May;61(2):227-32. doi: 10.1006/gyno.1996.0130. Gynecol Oncol. 1996. PMID: 8626138

10

Large loop excision of the transformation zone (LLETZ): a pathologic evaluation.

Messing MJ, Otken L, King LA, Gallup DG. Messing MJ, et al. Gynecol Oncol. 1994 Feb;52(2):207-11. doi: 10.1006/gyno.1994.1032. Gynecol Oncol. 1994. PMID: 8314140

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

117 results

Search Page

Filters